Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.
Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, Du X, Petrov A, Lassman ME, Jiang G, Liu F, Miller C, Tota LM, Zhou G, Zhang X, Sountis MM, Santoprete A, Capito' E, Chicchi GG, Thornberry N, Bianchi E, Pessi A, Marsh DJ, SinhaRoy R. Pocai A, et al. Among authors: pessi a. Diabetes. 2009 Oct;58(10):2258-66. doi: 10.2337/db09-0278. Epub 2009 Jul 14. Diabetes. 2009. PMID: 19602537 Free PMC article.
DPP-IV-resistant, long-acting oxyntomodulin derivatives.
Santoprete A, Capitò E, Carrington PE, Pocai A, Finotto M, Langella A, Ingallinella P, Zytko K, Bufali S, Cianetti S, Veneziano M, Bonelli F, Zhu L, Monteagudo E, Marsh DJ, Sinharoy R, Bianchi E, Pessi A. Santoprete A, et al. Among authors: pessi a. J Pept Sci. 2011 Apr;17(4):270-80. doi: 10.1002/psc.1328. Epub 2011 Feb 3. J Pept Sci. 2011. PMID: 21294225
Moreover, we identified a single substitution which can change the OXM pharmacological profile from a dual GLP1R/GCGR agonist to a selective GLP1R agonist. The latter finding enabled studies, described in detail in a separate study (Pocai A, Car …
Moreover, we identified a single substitution which can change the OXM pharmacological profile from a dual GLP1R/GCGR agonist …
Discovery of MK-1462: GLP-1 and Glucagon Receptor Dual Agonist for the Treatment of Obesity and Diabetes.
Palani A, Nawrocki AR, Orvieto F, Bianchi E, Mandić E, Pessi A, Huang C, Deng Q, Toussaint N, Walsh E, Reddy V, Ashley E, He H, Mumick S, Hawes B, Marsh D, Erion M, Nargund R, Carrington PE. Palani A, et al. Among authors: pessi a. ACS Med Chem Lett. 2022 Jul 21;13(8):1248-1254. doi: 10.1021/acsmedchemlett.2c00217. eCollection 2022 Aug 11. ACS Med Chem Lett. 2022. PMID: 35978682 Free PMC article.
Development of a neuromedin U-human serum albumin conjugate as a long-acting candidate for the treatment of obesity and diabetes. Comparison with the PEGylated peptide.
Neuner P, Peier AM, Talamo F, Ingallinella P, Lahm A, Barbato G, Di Marco A, Desai K, Zytko K, Qian Y, Du X, Ricci D, Monteagudo E, Laufer R, Pocai A, Bianchi E, Marsh DJ, Pessi A. Neuner P, et al. Among authors: pessi a. J Pept Sci. 2014 Jan;20(1):7-19. doi: 10.1002/psc.2582. Epub 2013 Nov 13. J Pept Sci. 2014. PMID: 24222478
ApoA-I mimetic peptides promote pre-β HDL formation in vivo causing remodeling of HDL and triglyceride accumulation at higher dose.
Carballo-Jane E, Chen Z, O'Neill E, Wang J, Burton C, Chang CH, Chen X, Eveland S, Frantz-Wattley B, Gagen K, Hubbard B, Ichetovkin M, Luell S, Meurer R, Song X, Strack A, Langella A, Cianetti S, Rech F, Capitò E, Bufali S, Veneziano M, Verdirame M, Bonelli F, Monteagudo E, Pessi A, Ingenito R, Bianchi E. Carballo-Jane E, et al. Among authors: pessi a. Bioorg Med Chem. 2010 Dec 15;18(24):8669-78. doi: 10.1016/j.bmc.2010.09.074. Epub 2010 Nov 4. Bioorg Med Chem. 2010. PMID: 21115285
141 results